Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 14 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Colestipol Hydrochloride Tablets. This approval allows Zydus to market the drug, which is used to help reduce elevated cholesterol levels in patients. The company notes that this is only the second generic application approved by the USFDA for this product.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases